ERBB2 and breast carcinoma: Candesartan prevented a small drop in LV function, while metoprolol succinate did not affect overall LVEF deterioration [83]. The other randomized placebo control trial, MANTICORE 101, included patients with HER2-positive early breast cancer and who were on trastuzumab as an adjuvant treatment.